Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
about
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
description
2019 nî lūn-bûn
@nan
2019年の論文
@ja
2019年学术文章
@wuu
2019年学术文章
@zh
2019年学术文章
@zh-cn
2019年学术文章
@zh-hans
2019年学术文章
@zh-my
2019年学术文章
@zh-sg
2019年學術文章
@yue
2019年學術文章
@zh-hant
name
Low-Dose Anti-Thymocyte Globul ...... : Two-Year Clinical Trial Data
@en
type
label
Low-Dose Anti-Thymocyte Globul ...... : Two-Year Clinical Trial Data
@en
prefLabel
Low-Dose Anti-Thymocyte Globul ...... : Two-Year Clinical Trial Data
@en
P2093
P50
P356
P1433
P1476
Low-Dose Anti-Thymocyte Globul ...... : Two-Year Clinical Trial Data
@en
P2093
Brian N Bundy
Darrell M Wilson
David A Baidal
Dorothy J Becker
Henry Rodriguez
J Lori Blanchfield
Jay S Skyler
Jennifer B Marks
Jessica L Miller
Linda A DiMeglio
P304
P356
10.2337/DB19-0057
P50
P577
2019-04-09T00:00:00Z